Clinical Trial Update: Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome [Phase 1]

View source ↗

Summary

Phase 1 safety study of a single intravesical dose of TTI-1612 in women with Interstitial Cystitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Cystitis

Drugs mentioned

• TTI-1612

Snippet

Sponsor: Trillium Therapeutics Inc. | Conditions: Interstitial Cystitis | Phase 1 | Status: COMPLETED